Lilly's Oral GLP-1, Orforglipron, Delivers Weight Loss of up to an Average of 27.3 Lbs in First of Two Pivotal Phase 3 Trials in Adults With Obesity

Eli Lilly Attain-1 Trial Shows Orforglipron's Efficacy and Safety at 72 Weeks

Eli Lilly to Submit Orforglipron for Regulatory Review by Year-End

Eli Lilly Orforglipron's Safety Profile Consistent With GLP-1 Agonists